Immunotherapy for Thyroid and Salivary Gland Cancers — Where It Actually Applies

Rarely. Most thyroid and salivary gland cancers are treated with surgery, and where needed radioactive iodine or radiotherapy. Immunotherapy is not standard care in either disease. It is considered in a small number of advanced, aggressive or biomarker-selected cases, usually after the established options have been used or ruled out.

Eligibility is confirmed on a reviewed pathology report and a full staging assessment, never on a scan report or a discharge summary alone. If immunotherapy has been offered for an ordinary papillary thyroid cancer, ask what that advice was based on before you agree to anything.

Subtype decides this, not the organ. In the thyroid it is anaplastic carcinoma, and biomarker-selected radioiodine-refractory disease, that reach the conversation. In the salivary glands it is non-adenoid-cystic carcinoma that has spread. Across both, mismatch-repair deficiency or a high mutational burden is the commonest reason it is considered at all.

Thyroid cancer subtypes

Salivary gland cancer subtypes

Ask for your exact histological subtype in writing. “Thyroid cancer” or “salivary gland tumour” on a discharge summary is not enough information to answer the immunotherapy question, and for salivary tumours in particular a specialist pathology review sometimes changes the subtype — and therefore the whole plan.

Thin, and we will not dress it up. There is no large randomised trial establishing checkpoint-inhibitor immunotherapy as standard care in either cancer. What exists is small single-arm studies, subgroup data from tumour-agnostic biomarker trials, and case series. NCCN and ESMO reflect that by treating it as a selected option, not a standard one.

• No practice-changing randomised trial in either disease. Much of what is known comes from small single-arm studies, and from the handful of patients with these cancers enrolled in basket trials that recruited many tumour types at once.
• In adenoid cystic carcinoma, responses are uncommon. Reported response rates to single-agent checkpoint inhibitors have been low across the small studies summarised in NCCN and ESMO guidance current in August 2026. These tumours carry few mutations and few immune cells, which is exactly the profile in which this treatment tends to do least.
• In other salivary carcinomas the picture is a little better and still modest — responses reported in a minority of patients. That is a description of small reported series, not a prediction for you.
• The strongest signal is biomarker-driven, not organ-driven. Where a tumour is mismatch-repair deficient or MSI-high, checkpoint-inhibitor immunotherapy has shown meaningful response rates across many different cancers in the tumour-agnostic data NCCN summarises. The catch is that this finding is uncommon in thyroid and salivary tumours.
• In anaplastic thyroid carcinoma it is usually part of a combination, not a treatment on its own, and much of the supporting data is early. Speed matters more than drug class here — airway assessment and a same-week plan come first.
• Long-term data in these specific cancers barely exists. How long any response lasts, and what late immune effects look like years afterwards in these groups, is genuinely unknown. We would rather say that than guess.
• A clinical trial is often the honest recommendation. For a rare subtype with weak evidence, a properly conducted trial can be the most sensible route. We can explain how trials work and how to look for one. We cannot promise you a place on one, or a result from it.

We deliberately do not put survival figures against this decision on a web page. Those numbers depend on your subtype, your stage, your fitness and the treatment you have already had, and they belong in a 45-minute consultation with your own reports open in front of you — not in a paragraph written for everybody.

Because they are biologically opposite. Salivary duct carcinoma often carries androgen receptor and HER2 targets, which give directed treatment options with a clearer track record. Adenoid cystic carcinoma carries very few mutations and very few immune cells — the profile in which checkpoint-inhibitor immunotherapy tends to achieve least.

This is why advice written for head and neck squamous cancer can mislead you here. Salivary gland cancers sit in the same anatomical region and follow different rules, and the same is true of the thyroid. If you want to see how eligibility and expectation-setting are handled in another uncommon cancer, immunotherapy for mesothelioma works through the same reasoning in a different organ.

Three findings change the answer: mismatch-repair deficiency or MSI-high status, a high tumour mutational burden, and for salivary duct carcinoma, androgen receptor and HER2 status. PD-L1 carries far less weight here than it does in lung or head and neck squamous cancer. Ask which of these your report already covers.

• Mismatch-repair deficiency (dMMR) and MSI status — usually checked first, because it is quick, relatively inexpensive and can be done on tissue you already have. A positive result is uncommon in these cancers, but it is the single finding most likely to change the plan.
• Tumour mutational burden (TMB) — needs a broader sequencing panel, costs more and takes longer. Worth doing when disease is advanced and options are narrowing, not at the first diagnosis of an ordinary papillary thyroid cancer.
• Androgen receptor and HER2 in salivary duct carcinoma — these are not immunotherapy tests, and here they matter more. Request them explicitly; they are sometimes left off a routine histopathology report.
• Driver gene changes in thyroid cancer — a specific gene change found in an anaplastic or medullary tumour usually points towards targeted therapy rather than immunotherapy, and that assessment comes first.
• PD-L1 is weaker evidence here than the marketing suggests. It is not the gate to treatment in thyroid or salivary gland cancer the way it is at other head and neck sites.
• Cost and turnaround are part of the decision. Broad sequencing panels are not cheap and results can take two to three weeks. All costs are indicative, as of August 2026, and you get the estimate before a test is sent, not after it comes back. If a result cannot change what you do next, we will say so rather than sending it.

In a fixed sequence: confirm the exact subtype on a reviewed pathology report, stage the disease properly, establish whether the standard options are genuinely finished, test for the markers that could change the plan, then take the whole picture to a tumour board. No single test decides it.

1. 1

   Confirm the exact subtype, in writing

   “Thyroid cancer” is not a diagnosis you can plan from. Papillary, follicular, medullary, poorly differentiated and anaplastic carcinomas behave differently and are treated differently. Salivary gland tumours have more than twenty recognised types in the WHO classification. Slides are re-read by a pathologist here before anything is offered, and for salivary tumours that review sometimes changes the subtype.

2. 2

   Stage the disease and separate local from spread

   Neck ultrasound and cross-sectional imaging for thyroid disease; MRI for salivary tumours, because it shows nerve involvement that a CT can miss. PET-CT is used for distant staging and later for response assessment; it is coordinated at partner imaging centres rather than performed at CION. A scan report on its own never establishes eligibility.

3. 3

   Establish whether standard treatment is genuinely finished

   This is the step most often skipped. For differentiated thyroid cancer that means surgery and radioactive iodine. For radioiodine-refractory disease it means targeted therapy. For salivary duct carcinoma it means receptor-directed options. Immunotherapy does not jump the queue ahead of treatments with better evidence, and we will tell you if it is being suggested out of turn.

4. 4

   Test for the markers that could change the plan, and take baseline bloods

   Mismatch-repair and MSI testing first, broader sequencing where the situation justifies it, receptor testing on salivary duct carcinoma. Thyroid, liver and kidney function and blood counts are recorded before any immunotherapy starts. Thyroid function matters twice over in this group, because the gland can be inflamed by the treatment and many patients here are already on thyroid hormone after surgery — the detail is covered in thyroid problems on immunotherapy.

5. 5

   Review autoimmune history and steroids, then take it to the tumour board

   Rheumatoid arthritis, existing thyroid disease, psoriasis, inflammatory bowel disease, past transplant, ongoing high-dose steroids and uncontrolled infection including tuberculosis are all raised here. Some rule immunotherapy out. Others simply mean closer monitoring. Medical, radiation and surgical oncologists then review the case together — not one doctor’s opinion.

6. 6

   A written plan and a cost estimate before the first cycle

   You receive the plan in writing, with what is being treated, what is expected of it and what happens if it does not work. The cost conversation happens before treatment starts rather than after it. All costs are indicative, as of August 2026.

Immunotherapy itself is given as day care at CION centres. The infusion runs over roughly 30 to 60 minutes, you are observed afterwards, and you go home the same day. Blood tests are done before every cycle. Response-assessment PET-CT is coordinated at partner imaging centres. CION does not provide CAR-T or other cell therapies; where such treatment is being considered, we say so plainly and refer. New diarrhoea, a rash, breathlessness, chest pain, severe tiredness or a fast heartbeat go to us the same day — call 1800 202 8726 rather than waiting for the next visit.

If immunotherapy has been raised for a thyroid or salivary gland cancer, these companion pages cover the questions that usually follow — how the same eligibility reasoning is applied in other uncommon cancers, where it genuinely has a defined place, and how treatment is organised across our centres.

• Immunotherapy for Testicular Cancer — another cancer where the honest answer is usually no, and useful if you want to see the same reasoning applied where established treatment already works well.
• Immunotherapy for Anal Cancer — a rarer cancer where checkpoint-inhibitor immunotherapy does have a defined place in advanced disease. A useful contrast with the thyroid picture.
• Immunotherapy for Mesothelioma — how eligibility, evidence and expectation-setting are handled in another uncommon cancer with a difficult evidence base.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is planned, delivered and monitored across our centres, and who makes the decision.

One Conversation Can Settle the Question

Whether immunotherapy applies to you depends on your exact subtype, your stage and what has already been tried — not on a search result. Bring your reports and we will read them with you.